Informações:
Falhas:
ID
23252
Descrição
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00382239
Link
https://clinicaltrials.gov/show/NCT00382239
Palavras-chave
Versões (1)
- 30/06/2017 30/06/2017 -
Transferido a
30 de junho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Type 2 Diabetes Mellitus NCT00382239
Eligibility Type 2 Diabetes Mellitus NCT00382239
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT00382239
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
Body Weight
Item
have a body weight of >=50 kg.
boolean
C0005910 (UMLS CUI [1])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Study Subject Participation Status | exenatide | Glucagon-Like Peptide 1 Analog
Item
have participated in this study previously, or any other study using exenatide or other glp-1 analogs.
boolean
C2348568 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C0061355 (UMLS CUI [3,1])
C0243071 (UMLS CUI [3,2])
C0167117 (UMLS CUI [2])
C0061355 (UMLS CUI [3,1])
C0243071 (UMLS CUI [3,2])
Insulin Exogenous
Item
are treated with any exogenous insulin within 3 months of screening.
boolean
C0021641 (UMLS CUI [1,1])
C0205228 (UMLS CUI [1,2])
C0205228 (UMLS CUI [1,2])
Pharmaceutical Preparations Affecting Gastrointestinal Motility | Nauzelin | Domperidone | Primperan
Item
are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): *drugs that directly affect gastrointestinal motility, including nauzelin® (domperidone), primperan®/terperan®
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
C1579773 (UMLS CUI [2])
C0013015 (UMLS CUI [3])
C0242395 (UMLS CUI [4])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
C1579773 (UMLS CUI [2])
C0013015 (UMLS CUI [3])
C0242395 (UMLS CUI [4])
Metoclopramide | itopride | Cisapride | mosapride | Trimebutine
Item
(metoclopramide), ganaton® (itopride), acenalin® (cisapride), gasmotin® (mosapride), or cerekinon® (trimebutine).
boolean
C0025853 (UMLS CUI [1])
C0531483 (UMLS CUI [2])
C0072916 (UMLS CUI [3])
C0526501 (UMLS CUI [4])
C0041023 (UMLS CUI [5])
C0531483 (UMLS CUI [2])
C0072916 (UMLS CUI [3])
C0526501 (UMLS CUI [4])
C0041023 (UMLS CUI [5])
Medical contraindication Pharmaceutical Preparations
Item
have characteristics contraindicating for concomitant medication, according to product-specific label.
boolean
C1301624 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
Drug Allergy Severe
Item
have severe allergy or hypersensitivity to any drug.
boolean
C0013182 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])